Kilitch drugs (India) Limited has submitted its quarterly compliance certificate to stock exchanges, fulfilling mandatory regulatory requirements under SEBI guidelines. The pharmaceutical company filed the certificate on 14th April, 2026, addressing dematerialisation processes for the quarter ended 31st March, 2026.

Regulatory Compliance Filing

The company submitted the certificate under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulation, 2018 to both BSE Limited and National Stock Exchange of India Limited. Managing Director Mukund Mehta signed the submission letter, which was digitally authenticated on 14th April, 2026.

Registrar Confirmation

MUFG Intime India Private Limited, formerly Link Intime India Private Limited, serves as the company's Registrar and Share Transfer Agent. The registrar provided confirmation on 3rd April, 2026, certifying compliance with dematerialisation requirements during the quarter.

The registrar confirmed that securities received from depository participants for dematerialisation during Q4FY26 were properly processed. All securities comprised in the certificates have been listed on stock exchanges where the company's earlier issued securities are traded.

Process Verification

MUFG Intime India confirmed several key compliance aspects:

• Securities received for dematerialisation were confirmed or rejected to depositories within prescribed timelines
• Security certificates received were mutilated and cancelled after due verification by depository participants
• Names of depositories were substituted in the register of members as registered owners
• All processes adhered to regulatory timelines and requirements

Corporate Communication

The filing was addressed to corporate relationship departments of both stock exchanges, with copies sent to NSDL and CDSL. Ashok Shetty, Sr. Vice President-Corporate Registry at MUFG Intime India, signed the registrar's confirmation certificate.

This quarterly filing demonstrates Kilitch Drugs (India) Limited's adherence to SEBI regulations governing depositories and participants, ensuring transparent and compliant dematerialisation processes for shareholders.

Kilitch Drugs (India) Limited has announced a significant corporate action with its Board of Directors approving a bonus share allotment in a 1:1 ratio. The decision was taken during the board meeting held on March 25, 2026, marking a major milestone for the pharmaceutical company's shareholders.

Bonus Share Allotment Details

The company has approved the allotment of 1,74,80,782 bonus equity shares of Rs. 10 each to its shareholders. Under the 1:1 ratio scheme, shareholders will receive one bonus equity share of Rs. 10 each for every one equity share of Rs. 10 each currently held. The record date for determining eligible shareholders has been fixed as March 24, 2026.

The bonus equity shares will rank pari-passu in all respects with the existing fully paid-up equity shares of the company, ensuring equal rights and benefits for all shareholders.

Impact on Share Capital Structure

The bonus issue has resulted in a significant expansion of the company's equity base:

The paid-up equity share capital has effectively doubled from Rs. 17.48 crore to Rs. 34.96 crore following the bonus share allotment.

Board Meeting Proceedings

The board meeting commenced at 10:30 hours and concluded at 12:05 hours on March 25, 2026. The decision was communicated to both BSE Limited and National Stock Exchange of India Limited in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The announcement was signed by Mukund Mehta, Managing Director of Kilitch Drugs (India) Limited, bearing DIN: 00147876. This bonus share allotment represents the company's commitment to rewarding its shareholders while strengthening its equity structure for future growth initiatives.